Stubbs Alderton & Markiles Partner Michael Sherman successfully represents Xaleron Pharmaceuticals against Actavis and Allergan Inc. in dispute over unfair competition in bringing to market a novel treatment for hay fever utilizing botulinum toxin. Confidential monetary settlement one month before trial vindicated Xaleron’s claims.
Read the full article here.
Stubbs Alderton & Markiles attorney representing Xaleron Pharmaceuticals is Michael A. Sherman.
For more information on our Business Litigation Practice, contact Michael A. Sherman at .
